title: Beta-Blockers: Current State of Knowledge and Perspectives.
abstract: It has been over half a century since propranolol, the first beta-blocker, was developed for medical treatment. Since that time a large number of compounds from this group have been synthesised and many are now in clinical use. The structure, function, pharmacokinetics, and mechanism of beta-blockers have been established. The possibilities for their use in treating different conditions continue to evolve. Since the discovery of later generation beta-blockers, such as carvedilol and nebivolol, the search for new compounds continues, and may include known substances with beta-blocking properties which could extend their therapeutic potential.
authors.affiliation: Department of Pharmaceutical Chemistry, Poznan University of Medical Sciences, Grunwaldzka 6,60-780 Poznan, Poland. mogrodo@ump.edu.pl.
authors.forename: Magdalena
authors.initials: M
authors.lastname: Ogrodowczyk
authors.forename: Katarzyna
authors.initials: K
authors.lastname: Dettlaff
authors.forename: Anna
authors.initials: A
authors.lastname: Jelinska
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D002626:Chemistry, Pharmaceutical / Q000639:trends*; D005901:Glaucoma / Q000188:drug therapy; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D006980:Hyperthyroidism / Q000188:drug therapy; D008881:Migraine Disorders / Q000188:drug therapy; D015394:Molecular Structure
chemical_list: D000319:Adrenergic beta-Antagonists